Clinical Updates in Treating Advanced Prostate Cancer - Episode 7

Use of Bone Protection Agents

,

Panelists discuss how the PEACE-3 trial explores the efficacy of combining radium-223 with enzalutamide in advanced prostate cancer, highlighting its potential to enhance therapeutic outcomes and survival rates.

EP. 1: Treatment Landscape and Sequencing of Therapies
EP. 2: Treatment Timelines Related to Disease State and Use of Monotherapy
EP. 3: Genetic Testing – Germline
EP. 4: Recent Data on ARPI-Based Combination Regimens
EP. 5: Genetic Testing – Somatic
EP. 6: ARPI-Based Combination Regimens – PEACE-3 (Radium-223 and enzalutamide)
Now Viewing
EP. 7: Use of Bone Protection Agents
EP. 8: ARPI-Based Combination Regimens – ARANOTE (Darolutamide and ADT)
EP. 9: ARPI-Based Combination Regimens – CONTACT-02 (Cabozantinib plus atezolizumab)
EP. 10: ARPI-Based Combination Regimens – SPLASH (177 Lu-PNT-2002)
EP. 11: Key Takeaways and Looking Ahead

Do you mandate for an mcrpc that all your patients on a bone health agent and antiresorptive, regardless of the therapy, and regardless of whether they have bone lesions?

Related Content:

Clinical Updates in Treating Advanced Prostate Cancer
ARPI-Based Combination Regimens – CONTACT-02 (Cabozantinib plus atezolizumab)
ARPI-Based Combination Regimens – SPLASH (177 Lu-PNT-2002)
Key Takeaways and Looking Ahead